Huntington National Bank’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.54K | Hold |
1
| – | – | ﹤0.01% | 2226 |
|
|
2025
Q4 | $2.54K | Hold |
1
| – | – | ﹤0.01% | 2149 |
|
|
2025
Q3 | $2.54K | Hold |
1
| – | – | ﹤0.01% | 2155 |
|
|
2025
Q2 | $2.54K | Sell |
1
-243
| -100% | -$32K | ﹤0.01% | 2157 |
|
|
2025
Q1 | $32.2K | Sell |
244
-188
| -44% | -$23.4K | ﹤0.01% | 1362 |
|
|
2024
Q4 | $36.1K | Sell |
432
-54
| -11% | -$4.44K | ﹤0.01% | 1343 |
|
|
2024
Q3 | $35.6K | Buy |
486
+57
| +13% | +$4.28K | ﹤0.01% | 1311 |
|
|
2024
Q2 | $29.4K | Sell |
429
-79
| -16% | -$5.48K | ﹤0.01% | 1344 |
|
|
2024
Q1 | $35.2K | Buy |
508
+22
| +5% | +$1.51K | ﹤0.01% | 1258 |
|
|
2023
Q4 | $34.8K | Sell |
486
-89
| -15% | -$5.12K | ﹤0.01% | 1223 |
|
|
2023
Q3 | $30K | Sell |
575
-89
| -13% | -$5.18K | ﹤0.01% | 1211 |
|
|
2023
Q2 | $42K | Buy |
664
+217
| +49% | +$13.5K | ﹤0.01% | 1109 |
|
|
2023
Q1 | $24.2K | Buy |
447
+97
| +28% | +$4.69K | ﹤0.01% | 1250 |
|
|
2022
Q4 | $18.5K | Sell |
350
-34
| -9% | -$1.7K | ﹤0.01% | 1310 |
|
|
2022
Q3 | $18K | Buy |
384
+23
| +6% | +$1.2K | ﹤0.01% | 1339 |
|
|
2022
Q2 | $21K | Buy |
361
+315
| +685% | +$17.9K | ﹤0.01% | 1322 |
|
|
2022
Q1 | $3K | Buy |
+46
| New | +$2.39K | ﹤0.01% | 1868 |
|
Huntington National Bank's ITCI Position: Q1 2026 in Review
Huntington National Bank held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q1 2026 at 1 share worth $2.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2226.
Huntington National Bank first reported a position in ITCI in Q1 2022 and has held it in 17 quarters since. The position peaked at $42K in Q2 2023. 1 fund tracked by Wall St. Rank holds ITCI as of Q1 2026.
- Huntington National Bank held 1 share of Intra-Cellular Therapies Inc. worth $2.54K as of Q1 2026.
- Huntington National Bank left its Intra-Cellular Therapies Inc. share count unchanged in Q1 2026.
- Intra-Cellular Therapies Inc. made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #2226 holding.
- Huntington National Bank first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and has held it in 17 quarters since.
- Huntington National Bank's Intra-Cellular Therapies Inc. position peaked at $42K in Q2 2023.
- 1 fund tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2026.
Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.